This pilot study indicates that multiparametric [<sup>18</sup>F]FDG/[<sup>18</sup>F]FMISO PET-MRI might provide complementary quantitative prognostic information on breast tumors including clinical endpoints and thus might be used to tailor treatment for precision medicine in breast cancer.
To measure ABCB1 function in tumors, we performed PET experiments using both [<sup>18</sup>F]AVT-011 and [<sup>18</sup>F]FDG in mice bearing orthotopic breast tumors (n = 7-10/group) expressing clinically relevant levels of ABCB1.
To develop a multiparametric [<sup>18</sup>F]FDG positron emission tomography/magnetic resonance imaging (PET/MRI) model for breast cancer diagnosis incorporating imaging biomarkers of breast tumors and contralateral healthy breast tissue.
To help interpret measurements in breast tissue and breast tumors from <sup>18</sup>F-FDG PET scans, we studied the influence of age in measurements of PET parameters in normal breast tissue and in a breast cancer (BC) population.
Using the newly-developed PEM with [<sup>18</sup>F]FDG, we are able to identify and characterize exactly the small breast tumors less than 10 mm in combination with the conventional PET/CT.
Preliminary in vivo preclinical evaluation of these eight [<sup>18</sup>F]fluoro-inositols as Positron Emission Tomography (PET) imaging agents in a breast tumour-bearing mouse model was performed and compared with [<sup>18</sup>F]-2-fluoro-2-deoxy-d-glucose ([<sup>18</sup>F]FDG).
Primary breast tumorFDG uptake is strongly influenced by EGFR status beyond that by other major biomarkers including hormone receptor and HER2 status, and EGFR expression is a strong independent predictor of high breast tumorFDG uptake.